SFX‐01 to enter Phase II/III trials to test efficacy against COVID-19 symptoms
The drug candidate SFX-01 is set to be studied in Phase II/III trials to test its efficacy at treating acute respiratory distress syndrome (ARDS), a complication of COVID‐19.